ASCO 2017 Report — Malignant Hematology

Highlights of new treatments for myeloma, leukemia, and lymphoma

At this year's annual meeting of the American Society of Clinical Oncology (ASCO 2017), held June 3 to 7 in Chicago, investigators discussed the latest findings in cancer research. The editors of NEJM Journal Watch Oncology and Hematology were on hand to report highlights of the conference. Here, Michael E. Williams, MD, ScM, reviews key presentations on new treatments for myeloma, leukemia, and lymphoma patients. All meeting abstracts can be viewed in the ASCO meeting library.

CAR-T-Cell Therapy for Relapsed or Refractory Myeloma

Chimeric antigen receptor T-cell (CAR-T) immunotherapy is highly active in acute lymphoblastic leukemia, chronic lymphocytic leukemia (CLL), and B-cell non-Hodgkin lymphoma (NHL). Fan and colleagues have now develop…

Author

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee